Limits...
Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.

Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, Legrand L, Humbert O, Casasnovas O, Brunotte F, Cochet A - PLoS ONE (2015)

Bottom Line: There was no significant difference between ROC curves.High TMTV0 value was predictive of poor PFS in all methodologies: 4-years PFS was 83% vs 42% (p = 0.006) for TMTV02.5, 83% vs 41% (p = 0.003) for TMTV041, 85% vs 40% (p<0.001) for TMTV0125 and 83% vs 42% (p = 0.004) for TMTV0140.However, no significant differences were found in term of prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, France; Le2i UMR CNRS 6306, Dijon, France; MRI Unit, Centre Hospitalier Régional Universitaire, Hôpital Le Bocage, Dijon, France.

ABSTRACT

Aim: To investigate the respective influence of software tool and total metabolic tumor volume (TMTV0) calculation method on prognostic stratification of baseline 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG-PET) in newly diagnosed Hodgkin lymphoma (HL).

Methods: 59 patients with newly diagnosed HL were retrospectively included. [18F]FDG-PET was performed before any treatment. Four sets of TMTV0 were calculated with Beth Israel (BI) software: based on an absolute threshold selecting voxel with standardized uptake value (SUV) >2.5 (TMTV02.5), applying a per-lesion threshold of 41% of the SUV max (TMTV041) and using a per-patient adapted threshold based on SUV max of the liver (>125% and >140% of SUV max of the liver background; TMTV0125 and TMTV0140). TMTV041 was also determined with commercial software for comparison of software tools. ROC curves were used to determine the optimal threshold for each TMTV0 to predict treatment failure.

Results: Median follow-up was 39 months. There was an excellent correlation between TMTV041 determined with BI and with the commercial software (r = 0.96, p<0.0001). The median TMTV0 value for TMTV041, TMTV02.5, TMTV0125 and TMTV0140 were respectively 160 (used as reference), 210 ([28;154] p = 0.005), 183 ([-4;114] p = 0.06) and 143 ml ([-58;64] p = 0.9). The respective optimal TMTV0 threshold and area under curve (AUC) for prediction of progression free survival (PFS) were respectively: 313 ml and 0.70, 432 ml and 0.68, 450 ml and 0.68, 330 ml and 0.68. There was no significant difference between ROC curves. High TMTV0 value was predictive of poor PFS in all methodologies: 4-years PFS was 83% vs 42% (p = 0.006) for TMTV02.5, 83% vs 41% (p = 0.003) for TMTV041, 85% vs 40% (p<0.001) for TMTV0125 and 83% vs 42% (p = 0.004) for TMTV0140.

Conclusion: In newly diagnosed HL, baseline metabolic tumor volume values were significantly influenced by the choice of the method used for determination of volume. However, no significant differences were found in term of prognosis.

No MeSH data available.


Related in: MedlinePlus

ROC curves according to software ROC curves using TMTV041 with Beth Israel plugin (red line) and the commercial software (black line).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608733&req=5

pone.0140830.g002: ROC curves according to software ROC curves using TMTV041 with Beth Israel plugin (red line) and the commercial software (black line).

Mentions: Concerning the prognosis value, no significant differences between the AUC could be seen using the two TMTV041 assessments (Fig 2). AUC was 0.70 for Beth Israel plugin and 0.72 for the commercial software (p = 0.19). The optimal cut-off to predict patient outcomes was 313ml for Beth Israel plugin and 225ml for the commercial software. Using those cut-offs both packages were able to predict the PFS with a 4 years PFS of 83% vs 41% (p = 0.003) for Beth Israel plugin and 85% vs 42% (p = 0.001) for the commercial software.


Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.

Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, Legrand L, Humbert O, Casasnovas O, Brunotte F, Cochet A - PLoS ONE (2015)

ROC curves according to software ROC curves using TMTV041 with Beth Israel plugin (red line) and the commercial software (black line).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608733&req=5

pone.0140830.g002: ROC curves according to software ROC curves using TMTV041 with Beth Israel plugin (red line) and the commercial software (black line).
Mentions: Concerning the prognosis value, no significant differences between the AUC could be seen using the two TMTV041 assessments (Fig 2). AUC was 0.70 for Beth Israel plugin and 0.72 for the commercial software (p = 0.19). The optimal cut-off to predict patient outcomes was 313ml for Beth Israel plugin and 225ml for the commercial software. Using those cut-offs both packages were able to predict the PFS with a 4 years PFS of 83% vs 41% (p = 0.003) for Beth Israel plugin and 85% vs 42% (p = 0.001) for the commercial software.

Bottom Line: There was no significant difference between ROC curves.High TMTV0 value was predictive of poor PFS in all methodologies: 4-years PFS was 83% vs 42% (p = 0.006) for TMTV02.5, 83% vs 41% (p = 0.003) for TMTV041, 85% vs 40% (p<0.001) for TMTV0125 and 83% vs 42% (p = 0.004) for TMTV0140.However, no significant differences were found in term of prognosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, France; Le2i UMR CNRS 6306, Dijon, France; MRI Unit, Centre Hospitalier Régional Universitaire, Hôpital Le Bocage, Dijon, France.

ABSTRACT

Aim: To investigate the respective influence of software tool and total metabolic tumor volume (TMTV0) calculation method on prognostic stratification of baseline 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography ([18F]FDG-PET) in newly diagnosed Hodgkin lymphoma (HL).

Methods: 59 patients with newly diagnosed HL were retrospectively included. [18F]FDG-PET was performed before any treatment. Four sets of TMTV0 were calculated with Beth Israel (BI) software: based on an absolute threshold selecting voxel with standardized uptake value (SUV) >2.5 (TMTV02.5), applying a per-lesion threshold of 41% of the SUV max (TMTV041) and using a per-patient adapted threshold based on SUV max of the liver (>125% and >140% of SUV max of the liver background; TMTV0125 and TMTV0140). TMTV041 was also determined with commercial software for comparison of software tools. ROC curves were used to determine the optimal threshold for each TMTV0 to predict treatment failure.

Results: Median follow-up was 39 months. There was an excellent correlation between TMTV041 determined with BI and with the commercial software (r = 0.96, p<0.0001). The median TMTV0 value for TMTV041, TMTV02.5, TMTV0125 and TMTV0140 were respectively 160 (used as reference), 210 ([28;154] p = 0.005), 183 ([-4;114] p = 0.06) and 143 ml ([-58;64] p = 0.9). The respective optimal TMTV0 threshold and area under curve (AUC) for prediction of progression free survival (PFS) were respectively: 313 ml and 0.70, 432 ml and 0.68, 450 ml and 0.68, 330 ml and 0.68. There was no significant difference between ROC curves. High TMTV0 value was predictive of poor PFS in all methodologies: 4-years PFS was 83% vs 42% (p = 0.006) for TMTV02.5, 83% vs 41% (p = 0.003) for TMTV041, 85% vs 40% (p<0.001) for TMTV0125 and 83% vs 42% (p = 0.004) for TMTV0140.

Conclusion: In newly diagnosed HL, baseline metabolic tumor volume values were significantly influenced by the choice of the method used for determination of volume. However, no significant differences were found in term of prognosis.

No MeSH data available.


Related in: MedlinePlus